What is InxMed?
Founded in 2018, InxMed operates as a specialized biotech entity dedicated to overcoming therapeutic resistance in oncology, particularly concerning anti-PD-1/PD-L1 treatments. The company distinguishes itself through a dual-focus approach: deep biological research into disease pathways and the construction of an efficient clinical translational science platform. With an operational footprint spanning Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, InxMed has established a differentiated pipeline. Its strategic positioning is further bolstered by collaborative partnerships with multinational pharmaceutical giants such as Merck, Roche, and Boehringer Ingelheim, facilitating a bridge between innovative drug discovery and global market access.
How much funding has InxMed raised?
InxMed has raised a total of $84M across 2 funding rounds:
Series A
$19M
Series B
$65M
Series A (2020): $19M with participation from China Growth Capital, InnoMed Capital, Ennovation Ventures, and Grand Yangtze Capital
Series B (2022): $65M led by CS Capital, eNNOVATE Health Ventures, AIHC Fund, Growth Fund, and Hosencare Fund
Key Investors in InxMed
CS Capital
CS Capital provides comprehensive financial support and advisory services to emerging enterprises, guiding them through capital market complexities and growth milestones.
eNNOVATE Health Ventures
eNNOVATE Health Ventures is a specialized healthcare consultancy and investment firm that partners with industry leaders to identify and capitalize on critical market opportunities.
China Growth Capital
China Growth Capital is a Beijing-based venture capital and private equity firm focused on identifying and nurturing high-potential companies within the Chinese market.
What's next for InxMed?
With the recent influx of capital, InxMed is well-positioned to scale its translational medicine capabilities and advance its proof-of-concept platform. The company's strategic roadmap involves leveraging these resources to navigate the complexities of late-stage clinical trials and expand its international footprint. By maintaining its focus on high-impact oncology therapeutics, InxMed aims to solidify its role as a critical player in the global biotech ecosystem, potentially setting the stage for future licensing agreements or further expansion into new therapeutic modalities.
See full InxMed company page
